ZIOPHARM Oncology, Inc.
1180 Avenue of the Americas
Suite 1920
New York,
NY 10036
United States - Map
Phone: 646-214-0700
Fax: 646-214-0711
Web Site: http://www.ziopharm.com
| ZIOPHARM Oncology, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of proprietary small molecule drug candidates that are related to cancer therapeutics. Its primary product includes Palifosfamide (Zymafos or ZIO-201), which is in phase II randomized controlled trial for the treatment of metastatic or unresectable soft tissue sarcoma as front- or second-line therapy. The companys products in Phase I and/or II studies include Darinaparsin (Zinapar or ZIO-101), a novel anti-mitochondrial agent for the treatment of acute promyelocytic leukemia and for various other cancers; and Indibulin (Zybulin or ZIO-301), a novel small molecular-weight tubulin polymerization inhibitor. It has collaboration agreement with Harmon Hill, LLC to provide consulting and other services related to the companys development and commercialization of oncology therapeutics. The company was founded in 2003 and is based in New York, New York. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Jonathan J. Lewis M.D., Ph.D., 50
Exec. Chairman and Chief Exec. Officer |
N/A
| N/A | Mr. Richard E. Bagley , 65
Pres, Chief Operating Officer, Chief Financial Officer, Principal Accounting Officer, Treasurer |
N/A
| N/A | Mr. Robert Morgan JD,
Sr. VP of Regulatory Affairs Quality and Clinical Devel. |
N/A
| N/A | Dr. Barry Jones Ph. D., 60
Sr. VP of Preclinical Operations |
N/A
| N/A | Dr. Barbara Wallner Ph.D., 66
Sr. VP of Technical Operations and Chief Technical Officer |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.10% Nasdaq 
0.07 (2.30%) 
Profile
